Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AKAP11
REST API REST API
Homo sapiens
AKAP11 is differentially expressed in 275 experiments: 113 organism parts: liver, bone marrow, ... (111 more);, 175 disease states: normal, control, ... (173 more);, 73 cell types 322 cell lines 40 compound treatments and 74 other conditions.
Synonyms PRKA11, DKFZp781I12161, KIAA0629, AKAP220, FLJ11304
Orthologs ENSGALG00000016960 (Gallus gallus)   AKAP11 (Bos taurus)   Akap11 (Mus musculus)   akap11 (Danio rerio)   ENSGALG00000022739 (Gallus gallus)   Akap11 (Rattus norvegicus)   akap11 (Xenopus laevis)   AKAP11 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytoskeleton, cytoplasm, protein phosphatase 1 binding, protein complex, protein kinase A binding, microtubule organizing center, intracellular protein kinase cascade, protein kinase A catalytic subunit binding, protein kinase A regulatory subunit binding, regulation of protein kinase A signaling cascade, protein complex scaffold
UniProt Accession Q9UKA4, Q6AI61
Search EB-eye ENSG00000023516
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (39 experiments)

Factor Value U/D Experiments
SW480
1
3
E-MEXP-1014, E-GEOD-2509, E-MTAB-37, E-GEOD-18005
HCC2157
2
E-MTAB-37, E-MTAB-62
MCF-7
2
E-GEOD-19639, E-GEOD-20081
HCC1937
1
E-MTAB-37
ANBL-6
1
E-MEXP-921
mcf7-lmo4-tetoff cells
1
E-MTAB-62
316 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-13987, E-GEOD-21750, E-GEOD-21909, E-GEOD-2822, ... (40 experiments)

Factor Value U/D Experiments
stromal cell
1
2
E-GEOD-3998, E-GEOD-1460, E-GEOD-10797
CD3- CD56dim CD62L+ NK cell
1
E-GEOD-21774
CD3- CD56dim CD62L- NK cell
1
E-GEOD-21774
germ cell
1
E-MTAB-25
CD19+ B cell
1
E-MEXP-1600
human embryonic stem cell
1
E-GEOD-18265
67 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (63 experiments)

Factor Value U/D Experiments
glioblastoma
1
3
E-GEOD-4290, E-GEOD-4412, E-MEXP-567, E-MTAB-62
control
1
3
E-GEOD-8121, E-GEOD-16363, E-GEOD-20295, E-GEOD-20168
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
acute promyelocytic leukemia
2
E-GEOD-1729, E-GEOD-995
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
colon carcinoma
2
E-MTAB-37, E-GEOD-3726
169 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-7400, E-GEOD-5258, E-GEOD-6907, E-GEOD-15205, ... (24 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
none
4
5
E-GEOD-5824, E-MEXP-1230, E-GEOD-7400, E-GEOD-412, E-TABM-868, ... (9 experiments)
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
Cxcl12
1
E-GEOD-7307
4,5-dianilinophthalimide
1
1
E-GEOD-5258
M-CSF
1
E-GEOD-5099
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-860, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-MEXP-2280, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-321, E-TABM-868, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-GEOD-12773, E-TABM-127, E-GEOD-20540, ... (10 experiments)

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (28 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-2634, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.446 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM